ISR Articles

  1. How Service Providers Can Create Momentum In An Established Brand 5/27/2022

    To promote brand growth, companies must identify which brand components are succeeding and which may be falling short, as well as understand how these dynamics manifest in the larger organization’s successes and failures.

  2. Reactor Technology's Influence On CDMO Selection 5/4/2022

    ISR asked 76 biopharma respondents that outsource commercialized products how much influence the contract manufacturer’s reactor technology has on their choice of CDMO. 

  3. Outsourcers Are Feeling Uneasy About Continuity Of Supply 4/14/2022

    Find out how COVID-19 complications have picked up from the first year, with more outsourcers experiencing bigger obstacles when it comes to manufacturing, specifically with drug product.

  4. Preference Among Users: New And Emerging Biopharma 4/13/2022

    ISR asked new and emerging biopharma respondents which CDMOs they are currently working with, and, if the choice were entirely up to them, which CDMO would they prefer.

  5. Understanding CDMO Selections: Getting It Right 3/25/2022

    Learn the importance of identifying CDMO key decision-makers and exploring how they reach determinations that reshape imprecise product-based marketing into messaging that addresses specific customer concerns.

  6. Use Of Preferred Providers Among Large Molecule Outsourcers 3/16/2022

    ISR surveyed outsourcers of biologic API and outsourcers of biologics drug products to ask whether their company uses a preferred providers list of contract manufacturers for outsourced manufacturing.

  7. Have CDMO Selection Criteria Changed Over The Past Five Years? 3/16/2022

    New relationship dynamics between sponsors and CDMOs contribute to new trends appearing in the outsourced activities and services as well as the way CDMO selection decisions are made. ISR shares how CDMO selection criteria has changed over the past five years and links the attributes to the Life Science Leader’s CDMO Leadership Awards categories.

     
  8. Biologic Drug Product Outsourcing Drivers By Company Size 2/14/2022

    The data show that sponsors from large pharma tend to use CMOs to augment internal manufacturing capacity (71%) while sponsors from non-large pharma use CMOs for all manufacturing needs (66%).

  9. What's Happening In Cell & Gene Therapy Development? 2/8/2022

    This ISR report provides support and direction for innovative companies looking to outsource aspects of their cell and gene therapy manufacturing and development through shared research highlights.

  10. Large Molecule Drug Substance Pandemic Complications 1/14/2022

    ISR asked respondents in its annual biologic drug substance benchmarking survey over the past two years whether they encountered pandemic related complications with their outsourced manufacturing. Learn why it was more common for large molecule drug substance outsourcers to experience COVID-19 related manufacturing complications in 2021 than during 2020.